“The absolute risk reduction in metastasis ranges from 2% to 12% by 10 years. Given this heterogeneity, there is a strong rationale for better prognostic markers to personalize treatment of prostate cancer. Nearly all men treated with androgen-deprivation therapy have variable side effects that decrease quality of life,” said invited study discussant Richard K. Valicenti, MD, FASTRO, of the University of California, Davis.
![Richard K. Valicenti, MD, FASTRO](/media/14016536/13-valicenti.jpg)
Richard K. Valicenti, MD, FASTRO
“Traditional criteria are not sufficient to individualize treatment for men with prostate cancer. Prognostic absolute risk estimators show great promise for a more personalized approach to the treatment of prostate cancer. Clinical and genomic classifiers may be able to estimate individual risk, so benefits outweigh the potential harm for a particular absolute risk reduction,” he continued.
Dr. Valicenti said that the results of Dr. Tward’s study “clearly justify testing of the combined clinical cell-cycle risk score in tiered and appropriately powered noninferiority prospective studies, according to National Comprehensive Cancer Network risk groups. Such studies could identify a highly individualized deintensified approach.”
DISCLOSURE: Dr. Valicenti has reported no conflicts of interest.